This year, the prescription drug landscape is shifting from a focus on rebates toward a more transparent view of net costs. For years, manufacturer rebates paid to pharmacy benefit managers (PBMs) have been key to drug pricing. These rebates were meant to lower overall spend but they sometimes hid the real costs paid by payers…